Aim: This study aims to assess the antioxidant property of vitamins E and C in Helicobacter pylori infection, and to determine if adding them to standard triple therapy plus bismuth subcitrate increases the H. pylori eradication rate.
Methods: This study included 160 patients infected with H. pylori, who were randomized into one of two groups. Patients in group A (n = 80) received lansoprazole (30 mg, b.i.d.), amoxicillin (1000 mg, b.i.d.), clarithromycin (500 mg, b.i.d.), and bismuth subcitrate (300 mg, q.i.d.) for 14 days, while patients in group B (n = 80) received vitamin C (500 mg, b.i.d.) and vitamin E (200 IU, b.i.d.) for 30 days, in addition to lansoprazole (30 mg, b.i.d.), amoxicillin (1000 mg, b.i.d.), clarithromycin (500 mg, b.i.d.), and bismuth subcitrate (300 mg, q.i.d.) for 14 days. Total antioxidant capacity (TAC) was evaluated with a Randox kit. Success rate was calculated using both intention-to-treat (ITT) and per-protocol (PP) analyses.
Results: One hundred and sixty patients were analyzed using ITT analysis. One hundred and fifty-three patients completed the study. In group A, H. pylori eradication was achieved in 48 (60%) of the 80 patients included in the ITT analysis, and in 48 (64%) of the 75 patients included in the PP analysis. In group B, H. pylori eradication was achieved in 73 (91.25%) of the 80 included in the ITT analysis and in 73 (93.5%) of the 78 patients included in the PP analysis. The eradication rate was significantly higher in group B than in group A (p < .005). TAC was at the lower limit of normal in both groups and the difference between them was not statistically significant (p > .05).
Conclusion: In group B, H. pylori eradication rate was 91.25%, which is higher than the ideal 80% eradication rate. The results of the present study show that adding the prescribed doses of vitamins E and C to antimicrobial therapy is effective in eradicating H. pylori infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1523-5378.2009.00686.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Understanding and Preventing Advanced Gastric Cancer in Young Hispanic Patients.
Cancer Epidemiol Biomarkers Prev
January 2025
Keck School of Medicine, University of Southern California, Los Angeles, California.
The risk of gastric cancer among immigrants from countries where Helicobacter pylori is endemic greatly exceeds those born in the United States. Among patients in the Los Angeles safety-net health system, the risk of advanced and fatal gastric cancer is higher in Hispanic versus non-Hispanic patients. There is an urgent need to define whether this reflects concomitant illnesses, such as metabolic disease, occupational exposures, or differential access to H.
View Article and Find Full Text PDFReal-world evidence on the efficacy and safety of vonoprazan-amoxicillin dual therapy for treatment in elderly patients.
World J Gastroenterol
January 2025
Department of Gastroenterology, Peking University First Hospital, Beijing 100034, China.
Background: A dual therapy regimen containing amoxicillin is a common treatment option for the eradication of (). While substantial research supports the efficacy and safety of vonoprazan and amoxicillin (VA) dual therapy in the general population, there is still a lack of studies specifically focusing on its safety in elderly patients.
Aim: To evaluate efficacy and safety of VA dual therapy as first-line or rescue treatment for in elderly patients.
Experience of Metronidazole Triple Therapy After Clarithromycin Triple Therapy Failure for Eradication in Korea.
J Clin Med
December 2024
Department of Internal Medicine, Gyeongsang National University College of Medicine, Gyeongsang National University Hospital, Jinju 52727, Republic of Korea.
Bismuth quadruple therapy (BQT) is recommended as the best second-line regimen after failure of first-line clarithromycin triple therapy (CTT) for eradication. However, there are some limitations to this approach, including the lack of an appropriate sequel regimen after failure of BQT and complicated administration. Metronidazole triple therapy (MTT) is simple to administer, but it is not widely recommended.
View Article and Find Full Text PDFEndoscopic and Histological Characteristics of Gastric Cancer Detected Long After Eradication Therapy.
Cancers (Basel)
December 2024
Department of Clinicopathology, Hiraka General Hospital, Yokote 013-8610, Akita, Japan.
Background/objectives: Since 2013, eradication therapy for gastritis (-ET) has been covered by the National Health Insurance of Japan. Recently, the risk of post-eradication gastric cancer (pE-GC) has increased. pE-GC includes cancers that develop immediately and several years after -ET.
View Article and Find Full Text PDFClinical features and temporal trends in H. pylori negative gastric maltoma.
Arab J Gastroenterol
January 2025
Division of Gastroenterology and Hepatology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address:
Article Synopsis
- Mucosa-Associated Lymphoid Tissue (MALT) lymphoma, particularly gastric MALToma, is often associated with Helicobacter pylori (H. pylori) infection, though a significant number of cases occur without it.
- A study analyzed 52 patients with gastric MALToma from 2000 to 2021, finding that 48.1% were H. pylori-negative (HPN) and noted trends of increased HPN diagnoses in more recent years.
- Treatment outcomes showed that HPP patients had better responses to eradication therapy compared to HPN patients, who were more likely to receive additional chemo or radiotherapy.
- Despite these differences in treatment response, clinical features between HPP and HPN patients
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!